With several narcolepsy treatments advancing, the race for market leadership remains open.
Fuelled by blockbusters such as Eliquis, Pfizer is cementing its post-Covid revenue legacy.
This funding round will set Mironid up until the generation of initial clinical data, the company’s CEO says.
Asymchem Group will contribute $156m while Hillhouse Qirui will invest nearly $26m.
Chugai scientists will use Biomni Lab to consolidate diverse biomedical resources in a single digital workspace.
